Thermo Fisher Scientific (TMO) and bioMerieux, Inc. Renew Partnership for Improved Detection of Sepsis Using PCT Biomarker
10/2/2012 9:54:32 AM
MARCY L'ETOILE, France & HENNIGSDORF, Germany--(BUSINESS WIRE)--bioMérieux and Thermo Fisher Scientific Inc., the world leader in serving science, today announced they have renewed their non-exclusive, long-term, royalty-bearing agreement for Procalcitonin (PCT) testing. This agreement extends a long-standing relationship between the companies for biomarker testing using Thermo Fisher’s PCT product on bioMérieux’s VIDAS® and mini VIDAS® immunoassay platforms, and now also includes the new-generation VIDAS® products.